BioSpace News Archive

RED pawn beating competition over white background. Standing out from the crowd. Business strategy, outsider becoming the leader.3D rendering on white background.

Rare diseases

Rare Disease Biotechs Stand To Lose $4B if Priority Voucher Program Not Reinstated: Report

Some 200 rare disease therapies are at risk of losing eligibility for a pediatric priority review voucher, a recent analysis by the Rare Disease Company Coalition shows. That could mean $4 billion in missed revenue for already cash-strapped biotechs.

January 26, 2026

·

7 min read

·

Heather McKenzie

Metaverse avatars of sandboxes games in virtual reality through VR goggles in the world of Metaverse 3D illustrations

Opinion

To Accelerate Rare Disease Progress, Take a Sandbox Approach

Together with robust data-driven modeling, rethinking regulation and data use could push forward a notoriously challenging field.

January 26, 2026

·

5 min read

·

Oxana Iliach

Set your goals is shown using the collage with aim and the hand. Business targeting, aiming, focus concept and way to achieve a goal

Ovarian cancer

Corcept’s Ovarian Cancer Drug Hits ‘Robust’ Efficacy in Phase III, Setting Up Challenge to Merck, AbbVie

Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities said Thursday.

January 26, 2026

·

2 min read

·

Tristan Manalac

Two hands locked in a handshake cut by a pair of scissors, symbolizing a severed relationship or partnership. Black and white collage illustration on paper textured background

Mergers & acquisitions

Merck Backs Off Revolution After Failing To Agree on Price: WSJ

Merck had previously offered anywhere from $28 billion to $32 billion to swallow Revolution Medicines.

January 26, 2026

·

1 min read

·

Tristan Manalac

Biotechnology and molecular genetic engineering. 3D illustration of science and molecular technology.

Duchenne muscular dystrophy

Sarepta’s DMD Gene Therapy Staves Off Disease Three Years After Treatment

After a spate of patient deaths in 2025 linked to the company’s Duchenne gene therapy, Sarepta shared new data showing benefits of the therapy three years after dosing.

January 26, 2026

·

2 min read

·

Dan Samorodnitsky

Brain neurons synapse in human head isolated on black background, 3D rendering.

Parkinson’s disease

5 Investigational Therapies That Could Change the Parkinson’s Landscape

From opening new therapeutic mechanisms to repairing neuronal damage, investigational molecules from Ventyx Therapeutics, AC Immune, Gain Therapeutics and more could shape the future of Parkinson’s disease treatment.

January 26, 2026

·

9 min read

·

Tristan Manalac